Luca Arecco/X
Jun 4, 2025, 08:14
Luca Arecco Presented in Clinical Science Symposium at ASCO25 – New data from CARRIERS study
Luca Arecco, Clinical Research Fellow at ESMO, shared a post on X:
“Presented in Clinical Science Symposium at ASCO25 new data from CARRIERS study
Among >25,000 patients with BC, germline BRCA1 and BRCA2 carriers were linked to worse OS in ER+ BC
No OS impact for ATM, CHEK2, or PALB2 (PALB2 a trend to worse OS)
In >25,000 women, PVs in ATM, BRCA1, BRCA2, CHEK2, or PALB2 were found in 6% Impact on OS was gene- and subtype-specific. For ER+ diseases: BRCA1: HR 1.8 (p=0.02) BRCA2: HR 1.8 (p<0.001)
Significant worse OS compared to non-carriers.
On the contrary, in ER-negative diseases no significant OS differences were observed across all PVs (BRCA1, BRCA2, ATM, CHEK2, PALB2) These results reinforce how tumor biology and endocrine sensitivity may drive prognosis in ER+ diseases!
In our analysis presented at ASCO24 and published in Annals Oncology we evaluated prognosis of young patients (<40y) affected by BC and harboring BRCA1 and BRCA2 PVs We included >4,500 young BRCA carriers, and these were the main findings:
– BRCA carriers with HR+ disease had similar prognosis of carriers with HR- disease
– BRCA2 carriers had worse prognosis (particularly BCSS) in year >5 from diagnosis
– Carriers with Luminal A-like diseases had poorer DFS than all the other subtypesBoth studies question the prognostic advantage of HR-positivity in BRCA carriers
HR+ BC in BRCA carriers (especially BRCA2) behave more aggressively than in sporadic cases
Time to re-evaluate (escalate) treatments in BRCA carriers with HR+ BC?”
Title: Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
A. Di Meglio
A. Fabi
A. Ferrari
A. Fontana
A. Matikas
A. Rodriguez Hernandez
A. Toss
A.H. Partridge
ASCO
ASCO 2025
ASCO25
C. Rousset-Jablonski
C. Vernieri
cancer
CARRIERS study
Clinical Science Symposium
D. Aguilar-y Méndez
E. Agostinetto
E. Blondeaux
E. Carrasco
E. de Azambuja
E. Sokolović
F. Puglisi
F.J. Couch
F.S. Hilbers
G Curigliano
H.J. Kim
H.L. Pais
I. Witzel
J. Bajpai
K. Pogoda
K. Punie
K.A. Phillips
L. Arecco
L. De Marchis
Luca Arecco
M. Bruzzone
M. Ceppi
M. Lambertini
M. Rozenblit
M.V. Dieci
N. Lopetegui-Lia
Oncology
R. Bas
R. Bernstein-Molho
R. Duchnowska
R. Fruscio
R. Pesce
S. Paluch-Shimon
S.L. Graff
S.M. Wong
T. Renaud
V. Sini
W. Cui
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 19:30
Jun 26, 2025, 17:54
Jun 26, 2025, 17:47
Jun 26, 2025, 17:29